Jounce Therapeutics Inc (NASDAQ:JNCE) has been given a consensus rating of “Hold” by the nine analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $13.75.
Several research analysts recently commented on the company. HC Wainwright set a $13.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 13th. Zacks Investment Research upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a research note on Tuesday, August 14th. Cowen restated a “hold” rating on shares of Jounce Therapeutics in a research note on Thursday, August 9th. JPMorgan Chase & Co. cut their price objective on Jounce Therapeutics from $12.00 to $10.00 and set a “hold” rating on the stock in a research note on Friday, August 10th. Finally, Raymond James cut their price objective on Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 23rd.
A number of hedge funds and other institutional investors have recently made changes to their positions in JNCE. Millennium Management LLC raised its stake in Jounce Therapeutics by 91.6% during the second quarter. Millennium Management LLC now owns 679,177 shares of the company’s stock valued at $5,202,000 after buying an additional 324,681 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock valued at $2,861,000 after buying an additional 266,126 shares in the last quarter. BlackRock Inc. raised its stake in Jounce Therapeutics by 22.2% during the second quarter. BlackRock Inc. now owns 1,394,905 shares of the company’s stock valued at $10,684,000 after buying an additional 253,120 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Jounce Therapeutics by 186.0% during the second quarter. Dimensional Fund Advisors LP now owns 314,831 shares of the company’s stock valued at $2,412,000 after buying an additional 204,762 shares in the last quarter. Finally, Bridgeway Capital Management Inc. acquired a new stake in Jounce Therapeutics during the third quarter valued at approximately $1,321,000. Hedge funds and other institutional investors own 82.60% of the company’s stock.
NASDAQ:JNCE opened at $4.32 on Monday. Jounce Therapeutics has a one year low of $3.30 and a one year high of $29.25. The stock has a market capitalization of $141.27 million, a P/E ratio of -7.58 and a beta of 5.00.
Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.11. Jounce Therapeutics had a negative return on equity of 29.58% and a negative net margin of 59.74%. The business had revenue of $14.53 million for the quarter, compared to analysts’ expectations of $12.80 million. Analysts forecast that Jounce Therapeutics will post -1.14 EPS for the current year.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Read More: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.